References
- Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med 2000;342:314-19
- Ben-Menachem E, Gabbai A, Hufnagel A, et al. Efficacy and safety of eslicarbazepine acetate (ESL) as add-on treatment in adults with refractory partial-onset seizures: BIA-2093-302 study. Epilepsia 2008;49(Suppl. 7):424-5
- Elger C, Bialer M, Cramer JA, et al. Eslicarbazepine acetate: a double-blind, add-on, placebo-controlled exploratory trial in adult patients with partial-onset seizures. Epilepsia 2007;48:497-504
- Elger C, Halasz P, Maia J, et al. Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: a randomized, double-blind, placebo-controlled, parallel-group phase III study. Epilepsia 2009;50:454-63
- Gil-Nagel A, Lopes-Lima J, Almeida L, et al. Efficacy and safety of 800 and 1200 mg eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures. Acta Neurol Scand 2009;120:281-7
- Ambrosio AF, Soares-Da-Silva P, Carvalho CM, et al. Mechanisms of action of carbamazepine and its derivatives, oxcarbazepine, BIA 2-093, and BIA 2-024. Neurochem Res 2002;27:121-30
- Benes J, Parada A, Figueiredo AA, et al. Anticonvulsant and sodium channel-blocking properties of novel 10,11- dihydro-5H-dibenz[b,f]azepine-5-carboxamide derivatives. J Med Chem 1999;42:2582-7
- Benés J, Soares-da-Silva P. Substituted dihydrodibenzo/B,F/azepine, method of their preparation, their use in the treatment of some central nervous system disorders, and pharmaceutical compositions containing them. USPTO Patent No. 5,753,646, May 19, 1998
- Almeida L, Bialer M, Soares-da-Silva P. Eslicarbazepine acetate. In: Shorvon S, Perucca E, Engel J (eds). The Treatment of Epilepsy, 3rd Edn. Oxford: Blackwell Publishing, 2009: 485-98
- Almeida L, Falcão A, Maia J, et al. Single-dose and steady-state pharmacokinetics of eslicarbazepine acetate (BIA 2-093) in healthy elderly and young subjects. J Clin Pharmacol 2005;45:1062-6
- Almeida L, Potgieter JH, Maia J, et al. Pharmacokinetics of eslicarbazepine acetate in patients with moderate hepatic impairment. Eur J Clin Pharmacol 2008;64:267-73
- Maia J, Almeida L, Falcão A, et al. Effect of renal impairment on the pharmacokinetics of eslicarbazepine acetate. Int J Clin Pharmacol Ther 2008;46:119-30
- Shank RP, Maryanoff BE. Molecular pharmacodynamics, clinical therapeutics, and pharmacokinetics of topiramate. CNS Neurosci Ther 2008;14:120-42
- Doose DR, Walker SA, Gisclon LG, et al. Single-dose pharmacokinetics and effect of food on the bioavailability of topiramate, a novel antiepileptic drug. J Clin Pharmacol 1996;36:884-91
- Caldwell GW, Wu WN, Masucci JA, et al. Metabolism and excretion of the antiepileptic/antimigraine drug, topiramate in animals and humans. Eur J Drug Metab Pharmacokinet 2005;30:151-64
- Bourgeois BF. Drug interaction profile of topiramate. Epilepsia 1996;37(Suppl. 2):S14-17
- Nallani SC, Glauser TA, Hariparsad N, et al. Dose-dependent induction of cytochrome P450 (CYP) 3A4 and activation of pregnane X receptor by topiramate. Epilepsia 2003;44:1521-8
- Vaz da Silva M, Costa R, Soares E, et al. Effect of eslicarbazepine acetate on the pharmacokinetics of digoxin in healthy subjects. Fundam Clin Pharmacol 2009;23:509-14